Earn CME: https://naccme.com/program/19-gdugi-4 In this webcast from the ‘Exploring the Evolving Role of Immunotherapy in Advanced Hepatocellular Carcinoma: Considerations for Therapeutic Selection, Toxicity Management, and Sequencing’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Tanios S. Bekaii-Saab discusses the optimal sequencing of current and emerging agents for the treatment of hepatocellular carcinoma (HCC). © 2019 Imedex, an HMP Company
Optimal Sequencing of HCC Agents in the Era of Immunotherapy and Novel Agents and Targets
